- Moderna Inc (NASDAQ: MRNA) has received emergency use approval for its mRNA COVID-19 vaccine in Japan.
- Takeda Pharmaceutical Co Ltd (NYSE: TAK), which is in deal with Moderna, will begin the vaccine distribution in Japan immediately.
- Moderna’s COVID-19 vaccine is authorized for emergency use in adults aged 18 years and older.
- The latest approval is based on Moderna’s Phase 3 COVE study results and positive initial clinical data from the Takeda-led placebo-controlled Phase 1/2 study.
- The results showed an immune response consistent with Moderna’s pivotal Phase 3 COVE trial conducted in the U.S.
- Previously, the companies had announced that Takeda would handle about 50 million Moderna doses, beginning in the first half of 2021.
- It was also affirmed discussions for an additional potential supply of 50 million doses from the beginning of 2022.
- Price Action: MRNA shares are up 1.6% at $168.61, and TAK shares are up by 0.92% at $17.48 during the premarket session on the last check Friday.
After Initial Skepticism FDA’s Adcomm Backs Amylyx’s Amyotrophic Lateral Sclerosis Hopeful
The FDA Peripheral and Central Nervous System Drugs Advisory Committee voted (7 yes and 2 no) that the…
